source
- Alnylam shares tumble to $250 after cutting full-year revenue guidance for its TTR franchiseAlnylam Pharmaceuticals saw its share price slide to about $250 after the company lowered its full-year revenue outlook for its transthyretin (TTR) franchise. The guidance cut, announced in July, f…
- FDA approves first generic weekly hormone patch for menopausal womenThe U.S. Food and Drug Administration has granted approval for a generic version of a once‑weekly transdermal hormone patch that combines estradiol and levonorgestrel. The product matches the brand…